---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068599"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:05:41.014241+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences Q1 net loss $23.9M; cash $240.8M; Phase 2 canvuparatide data due 3Q25

## Summary
- Net loss $23.9M (vs $12.3M YoY); R&D $22.4M (up 103% YoY) on MBX 4291 and canvuparatide trials.
- Cash, cash equivalents & marketable securities $240.8M; expected to fund operations into mid-2027.
- Phase 2 Avail topline results for canvuparatide in hypoparathyroidism expected in 3Q 2025.
- IND submission for MBX 4291 (GLP-1/GIP co-agonist for obesity) on track for Q2 2025.
- Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia expected to start H2 2025.

## SEC filing metadata
- accession: 0000950170-25-068599
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/0000950170-25-068599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000095017025068599/mbx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068599
- JSON: https://secwatch.observer/filing/0000950170-25-068599.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.